About Nucleolysin TIAR
Nucleolysin TIAR (TIAL1) is a protein
from Homo sapiens identified by UniProt accession
Q01085, 375 residues long.
MolForge cross-references it against 0 known binders and
177 disease associations.
Target properties
| Protein name | Nucleolysin TIAR |
|---|
| UniProt accession | Q01085 |
|---|
| Gene | TIAL1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 375 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (177)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.37
- glioblastoma multiforme · score 0.23
- breast adenocarcinoma · score 0.23
- depressive symptom measurement · score 0.20
- stressful life event measurement · score 0.20
- cutaneous melanoma · score 0.18
- monocyte percentage of leukocytes · score 0.12
- head and neck squamous cell carcinoma · score 0.11
- myeloid white cell count · score 0.08
- neutrophil count · score 0.08
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q01085-F1 | alphafold | PREDICTED | 75.53 | — |
Amino-acid sequence (375 residues)
MMEDDGQPRT LYVGNLSRDV TEVLILQLFS QIGPCKSCKM ITEHTSNDPY CFVEFYEHRD AAAALAAMNG RKILGKEVKV NWATTPSSQK KDTSNHFHVF VGDLSPEITT EDIKSAFAPF GKISDARVVK DMATGKSKGY GFVSFYNKLD AENAIVHMGG QWLGGRQIRT NWATRKPPAP KSTQENNTKQ LRFEDVVNQS SPKNCTVYCG GIASGLTDQL MRQTFSPFGQ IMEIRVFPEK GYSFVRFSTH ESAAHAIVSV NGTTIEGHVV KCYWGKESPD MTKNFQQVDY SQWGQWSQVY GNPQQYGQYM ANGWQVPPYG VYGQPWNQQG FGVDQSPSAA WMGGFGAQPP QGQAPPPVIP PPNQAGYGMA SYQTQ
Explore Nucleolysin TIAR with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets